Author

C.C. Jackson

Observed names: C. C. Jackson, CC Jackson

Institution: Janssen Research & Development (United States)

Observed institution: Janssen Research & Development (United States)

OpenAlex ID: A5113048346

P961: Ciltacabtagene Autoleucel, a Bcma-directed Car-t Cell Therapy, in Patients With Relapsed/refractory Multiple Myeloma: 2-year Post Lpi Results From the Phase 1b/2 Cartitude-1 Study

2022 · Y. Lin, T. Martin, et al. · HemaSphere · 3

EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma

2022 · T Martin, SZ Usmani, et al. · Value in Health · 2

B09 Cartitude-2 Cohort B 18-month Follow-up: Ciltacabtagene Autoleucel (cilta-cel), a Bcma-directed Car-t Cell Therapy, in Patients With Multiple Myeloma (mm) and Early Relapse After Initial Therapy

2023 · S. Zweegman, M. Agha, et al. · HemaSphere · 1

P28 Efficacy and Safety of Ciltacabtagene Autoleucel (cilta-cel) in Patients With Progressive Multiple Myeloma (mm) After Exposure to Non-cellular Anti-b-cell Maturation Antigen (bcma) Immunotherapy

2023 · N. van de Donk, M.-V. Mateos, et al. · HemaSphere

Works count: 4

Citation count: 6

H-index: 2

I10-index: